Business Segments · Impairment charges, after tax
Life Sciences — Impairment charges, after tax
Danaher Life Sciences — Impairment charges, after tax increased by 94.1% to $328.00M in Q2 2025 compared to the prior quarter. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementSegment
CategoryProfitability
SignalLower is better
VolatilityModerate
First reportedQ3 2024
Last reportedQ2 2025
How to read this metric
An increase suggests declining asset performance or a deterioration in the business outlook for the specific segment.
Detailed definition
This metric represents the after-tax reduction in the carrying value of assets, such as long-lived assets or intangible...
Peer comparison
Comparable to 'Asset Impairment Charges' reported by peers in the life sciences and industrial sectors.
Metric ID:
dhr_segment_life_sciences_impairment_charges_after_taxHistorical Data
2 periods
| Q3 '24 | Q2 '25 | |
|---|---|---|
| Value | $169.00M | $328.00M |
| QoQ Change | — | +94.1% |
Range$169.00M – $328.00M
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Danaher's life sciences — impairment charges, after tax?
- Danaher (DHR) reported life sciences — impairment charges, after tax of $328.00M in Q2 2025.
- What does life sciences — impairment charges, after tax mean?
- The after-tax cost recognized when the value of an asset is written down because it is no longer worth its original book value.